PRESS RELEASE published on 03/10/2023 at 17:00, 3 years 6 months ago Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
PRESS RELEASE published on 02/28/2023 at 13:30, 3 years 6 months ago Moderna to Present at Cowen's 43rd Annual Health Care Conference
PRESS RELEASE published on 02/23/2023 at 13:00, 3 years 6 months ago Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
PRESS RELEASE published on 02/22/2023 at 22:05, 3 years 6 months ago Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela
PRESS RELEASE published on 02/22/2023 at 13:00, 3 years 6 months ago Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
PRESS RELEASE published on 02/17/2023 at 17:00, 3 years 6 months ago Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
PRESS RELEASE published on 02/16/2023 at 22:05, 3 years 7 months ago Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
PRESS RELEASE published on 02/02/2023 at 13:00, 3 years 7 months ago Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
PRESS RELEASE published on 01/30/2023 at 13:15, 3 years 7 months ago Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
PRESS RELEASE published on 01/17/2023 at 22:05, 3 years 7 months ago Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
Published on 09/16/2026 at 23:45, 5 hours 3 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 7 hours 18 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 11 hours 53 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 13 hours 48 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 14 hours 48 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/17/2026 at 04:25, 22 minutes ago Zhou Jianjun from Huawei: Building a Grid-Interactive AIDC Solution to Maximize Tokens Per Watt
Published on 09/16/2026 at 23:45, 5 hours 2 minutes ago WESCAN GOLDFIELDS COMMENCES UAV MAGNETIC AND LIDAR SURVEYS AT MUNRO LAKE PROJECT
Published on 09/16/2026 at 22:33, 6 hours 14 minutes ago EQS-Adhoc: Bilfinger adjusts outlook for 2026 and resolves program “Agile”
Published on 09/16/2026 at 21:15, 7 hours 32 minutes ago Gastech 2026 in Bangkok Converts Global Energy Ambition into Billions of Dollars in Deals
Published on 09/16/2026 at 20:27, 8 hours 20 minutes ago EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 17:45, 11 hours 3 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 21 hours 48 minutes ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 10 hours ago Report on the Combined General Meeting of the 10th of September 2026
